A study to investigate the safety and tolerability of SDL-M1 nanoparticles in healthy volunteers

2024-518889-27-00 Protocol SDL-M001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 2 Apr 2026 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol SDL-M001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 48
Countries 1
Sites 1

Septic cholestasis

Key facts

Sponsor
SmartDyeLivery GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Bacterial Infections and Mycoses [C01]
Trial duration
2 Apr 2026 → ongoing
Decision date (initial)
2024-11-15
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-518889-27-00
EudraCT number
2022-003872-18

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Septic cholestasis

VersionLevelCodeTermSystem organ class
20.0 LLT 10008638 Cholestasis intrahepatic 10019805

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

SmartDyeLivery GmbH

Sponsor organisation
SmartDyeLivery GmbH
Address
Botzstrasse 5, West West
City
Jena
Postcode
07743
Country
Germany

Scientific contact point

Organisation
SmartDyeLivery GmbH
Contact name
Clinical Trial Management

Public contact point

Organisation
SmartDyeLivery GmbH
Contact name
Clinical Trial Management

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruitment ended 48 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruitment ended
Charite Research Organisation GmbH
N/A, Chariteplatz 1, Mitte, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-01-31 2025-01-31 2025-12-12

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 2 · Art. 38 CTR

Temporary halt TH-112037

Halt date
2025-12-12
Member states concerned
Germany
Publication date
2025-12-18
Reason
Sponsor decision
Explanation
Please refer to the attached document.
Follow-up measures
Please refer to the attached document.
Benefit-risk balance changed
No
Treatment stopped
Yes

Temporary halt TH-88481

Halt date
2025-06-25
Member states concerned
Germany
Publication date
2025-06-30
Reason
Sponsor decision
Explanation
Please refer to the attached document.
Benefit-risk balance changed
No
Treatment stopped
No

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-17 Germany Acceptable
2024-11-06
2024-11-15
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-11 Germany Acceptable
2025-01-30
2025-01-31
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-02-11 Germany Acceptable
2025-01-30
2025-02-11
4 SUBSTANTIAL MODIFICATION SM-2 2025-07-24 Germany Acceptable
2025-08-13
2025-08-13
5 SUBSTANTIAL MODIFICATION SM-3 2025-08-27 Germany Acceptable
2025-09-17
2025-09-18
6 SUBSTANTIAL MODIFICATION SM-4 2025-10-23 Germany Acceptable
2025-11-10
2025-11-11
7 SUBSTANTIAL MODIFICATION SM-5 2026-04-02 Germany Acceptable
2026-04-17
2026-04-20